WHO ICTRP trial
Topical 5% Imiquimod cream for vulvar Paget's disease: clinical efficacy, safety…
NL-OMON42251 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON42251 |
|---|---|
| Public title | Topical 5% Imiquimod cream for vulvar Paget's disease: clinical efficacy, safety and immunological response |
| Scientific title | Topical 5% Imiquimod cream for vulvar Paget's disease: clinical efficacy, safety and immunological response - Paget trial |
| Primary sponsor | Radboud Universitair Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | vulvar extramammary paget's disease; vulvar paget's disease;10047789;vulvar extramammary paget's disease; vulvar paget's disease |
| Interventions | All patients use topical 5% imiquimod cream 3 times a week for 16 weeks. In case of side effects patients are allowed to use lidocain ointment and/or painkillers, or to adjust the frequency to 2 times a week or to pause treatment for 1… |
| Registration date | Oct 20, 2015 |
| Target size | 20 |
| Secondary IDs | 2014-005276-29 ;NCT02385188;NL51648.091.14 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: